Alnylam Pharmaceuticals, Inc.
High uncertainty:The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-85.7% vs price
Base Case (Median)
-79.6% vs price
Bull Case (75th pct.)
-67.0% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $43.37 | -80.7% | High (40%) |
| PE Comparable | $131.75 | -41.3% | Medium (25%) |
| Graham Number | $28.33 | -87.4% | Medium (40%) |
| EV/EBITDA | $48.20 | -78.5% | Medium (20%) |
| EV/FCF | $82.83 | -63.1% | Medium (20%) |
| Earnings Power Value | $3.38 | -98.5% | Medium (50%) |
Based on 6 out of 8 methods, ALNY appears overvalued at the current price of $224.60. The base case fair value of $45.79 implies 79.6% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.